In acute overdose clinical manifestations do not arise. With long-term use of the drug in doses greatly exceeding the recommended, may develop omnadren 250 jelfa systemic glucocorticosteroid effect as hypercortisolism and adrenal suppression.
Interaction with other drugs
Budesonide was observed interaction with other drugs used in the treatment of bronchial asthma.
Ketoconazole (200 mg once daily) increases the plasma concentrations of oral budesonide (3 mg once daily) on average 6-fold at the joint reception. When receiving ketoconazole by 12 hours after receiving the last concentration of budesonide in the plasma increased on average 3 times. Information about such interactions when taking budesonide inhalation in the form is missing, but it is assumed that in this case we should expect an increase of budesonide plasma concentrations. If necessary, the receiving ketoconazole and budesonide should increase the time between taking the drug to the maximum possible. You should also consider reducing the dose of budesonide. Another potential inhibitor, such as itraconazole, and significantly increases the plasma concentration of budesonide.
Preliminary inhaled beta-agonists extends bronchi improves delivery of budesonide to the respiratory tract and enhances its therapeutic effect.
Phenobarbital, phenytoin, rifampin reduce the effectiveness (induction of enzymes of microsomal oxidation) budesonide .
Methandrostenolone, estrogens increase the effect of budesonide.
To minimize the risk of fungal infections of the oropharynx of the patient should be instructed about the need to thoroughly rinse your mouth with water after each inhalation of the drug.
Avoid concomitant administration of budesonide with ketoconazole, itraconazole or other potent inhibitors of . If budesonide and ketoconazole or other potential inhibitors of omnadren 250 jelfa have been assigned, you should increase the time between drug administration to the maximum possible.
Because of the possible risk of impaired adrenal function, special attention should be given to patients who are transferred from oral glucocorticosteroids Pulmicort on reception. Also, special attention should be given to patients receiving high-dose corticosteroids, or long-term receives the highest possible recommended dose of inhaled glucocorticosteroids. In stressful situations, such patients may show signs and symptoms of adrenal insufficiency. When stress or in cases surgery is recommended additional systemic glucocorticosteroid therapy. Particular attention should be paid to patients who are transferred from systemic corticosteroids to inhaled (Pulmicort), or when you can expect a breach of pituitary-adrenal function.
Such patients should take special care to reduce the dose of systemic glucocorticosteroids and control of the hypothalamic-pituitary-adrenal axis function. Patients may also need to add oral corticosteroids during stressful situations such as trauma, surgery, etc.
In the transition from oral glucocorticosteroids Pulmicort on patients can feel the previously observed symptoms such as muscle aches or joint pain. In such cases, you may need a temporary increase in the dose of oral glucocorticosteroids. In rare cases, there may be symptoms such as fatigue, headache, nausea and vomiting, suggestive of systemic failure glucocorticosteroids.
Replacement of oral corticosteroids to inhaled sometimes leads to the manifestation of concomitant allergies, eg rhinitis and eczema, which were previously stoped systemic therapy.
In children and adolescents treated with corticosteroids (regardless of mode of delivery) over an extended period, to regularly monitor the growth rate. In the appointment of glucocorticosteroids omnadren 250 jelfa should take into account the ratio of use of the drug and the possible risk of growth retardation.
The use of budesonide in a dose of 400 mg a day for children older than 3 years did not lead to the emergence of systemic effects. Biochemical signs of systemic drug effects can occur when taking the drug at a dose of 400 to 800 micrograms per day. In excess doses of 800 micrograms per day systemic effects of the drug are common. The use of corticosteroids to treat asthma can cause dysplasia. The results of observations of children and adolescents treated with budesonide for a prolonged period (up to 11 years), showed that patients reaching the expected growth of standard indicators for adults.
Treatment with inhaled budesonide 1 or 2 times a day showed efficacy for the prevention of asthma physical effort.